NeoRx treats first patient with picoplatin in prostate cancer trial

By Elaine Rigoli

Tampa, Fla., May 31 - NeoRx Corp, which is changing its name to Poniard Pharmaceuticals, Inc. effective June 16, announced treatment of the first patient in a phase 1/ 2 clinical trial evaluating picoplatin for the potential front-line treatment of hormone-refractory metastatic prostate cancer.

An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance associated with the treatment of solid tumors, NeoRx said in a news release.

The phase 1/ 2 study is evaluating picoplatin as front-line therapy in the treatment of patients with stage 4 (metastatic) hormone-refractory prostate cancer who are newly diagnosed and have not received previous chemotherapy.

The multi-center trial is designed to determine the safety and efficacy of picoplatin when administered every three weeks with docetaxel.

In addition, picoplatin is being studied in an ongoing multi-center phase 2 clinical trial in patients with small cell lung cancer and in a phase 1/ 2 clinical trial as a potential front-line treatment for metastatic colorectal cancer, the release said.

NeoRx is a global specialty pharmaceutical company located in Seattle.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.